Abstract
To the Editor: Erlotinib (Tarceva; Genentech, South San Francisco, CA) is an oral anticancer agent that blocks the function of the epidermal growth factor receptor (EGFR) and has been approved by the US Food and Drug Administration for the treatment of non–small cell lung and pancreatic cancers. Therapy is frequently complicated by multiple cutaneous adverse effects ranging from follicular papulopustular (“acneiform”) eruptions, xerosis, nail changes (including paronychia and pyogenic granulomas in the lateral nail folds), and hair texture changes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
